Precision Biosensor

Precision Biosensor DSCR

The Debt Service Coverage Ratio (DSCR) of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is -1.01. In the previous year, Debt Service Coverage Ratio (DSCR) was -0.29 — a change of 246.03% (lower).

DSCR

-1.01

YoY

246.03%

Last updated:

Debt Service Coverage Ratio (DSCR) of Precision Biosensor is 2025 -1.01 . Debt Service Coverage Ratio (DSCR) of Precision Biosensor was 2024 -0.29 . It decreases by 246.03% lower compared to the previous year.

The Precision Biosensor DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2017
-9,043.44 KRW
Jan 1, 2019
-5.63 KRW
Jan 1, 2020
-7.19 KRW
Jan 1, 2021
-0.48 KRW
Jan 1, 2022
-0.55 KRW
Jan 1, 2023
-0.16 KRW
Jan 1, 2024
-0.29 KRW
Jan 1, 2025
-1.01 KRW
The Precision Biosensor DSCR history
YEARDSCRYoY
-1.01+246.03%
-0.29+78.34%
-0.16-70.08%
-0.55+13.98%
-0.48-93.34%
-7.19+27.84%
-5.63-99.94%
-9,043.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Debt Service Coverage Ratio (DSCR) of Precision Biosensor is -1.01 in 2025.

Debt Service Coverage Ratio (DSCR) of Precision Biosensor changed from -0.29 to -1.01, representing a 246.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Precision Biosensor with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Precision Biosensor

All Key Metrics — Precision Biosensor